Celosia Therapeutics is hoping to use gene therapy to treat neurodegenerative diseases such as Motor Neurone Disease (MND).

Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...

In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

Could Neuralink's brain implant be used to control a robotic arm? Neuralink is therefore launching a new feasibility trial, aimed at extending control of the brain-computer interface using the N1 ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...

LYON, France I6, 2024 I MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

A team at the Montreal Neurological Institute and Hospital – the Neuro – has been helping patients suffering from terminal neurological diseases. The Susan Cameron Cook Neuro-Palliative Care Program ...

A biotech start-up that has shown the ability to pause and in some cases reverse neurodegenerative diseases in mice has ...

Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, has completed one of the largest Series A ...

Sydney-based biotechnology company Celosia Therapeutics has secured $16.75 million in Series A funding to advance its ...